Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Jim Cash who wrote (22)	12/14/1997 10:53:00 PM
From: Mason Barge	Read Replies (2) \| Respond to of 422

Subject: Meeting / Non-event Date: Thu, Dec 11, 1997 19:59 EST From: ET FSU Message-id: <19971212005901.TAA29447@ladder01.news.aol.com> Straightforward acceptance of blame for internal / external auditors not catching loans. Not a financial risk to company and will be closed issue by March. More important ... FDA has at least acknowledged "they have begun" THE review .... small projects take a couple of weeks ... big projects a couple of months. This is a BIG project and they treat the safety of the nation's blood supply as a vital interest. This is good and bad. Once you are approved its damn hard for another competitor to start the process and catch up to you. Business has its good side and some important accounts have been opened up. The holy grail though is if/when a red cross center buys into a new test. BIG volumes. my gut feel is fda reviews and approves by march / april. roll out is one per week for 26 weeks, then 2 per week for rest of year til they can support 4 per week goal. This next quarter should be good and we should have good news to boot. good luck to the patient ... ( no pun intended).